Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000287

Drug Information
Trade NameIncrelex    
IndicationIGF-1 deficiencyApproved    [1]
Therapeutic ClassImmunomodulatory Agents    
CAS NumberCAS 68562-41-4
TargetInsulin-like growth factor I receptorInhibitor[2][3][4][5]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45. Epub 2003 Jul 5. To Reference
Ref 3One of two chondrocyte-expressed isoforms of cartilage intermediate-layer protein functions as an insulin-like growth factor 1 antagonist. Arthritis Rheum. 2003 May;48(5):1302-14. To Reference
Ref 4Analysis of the human type I insulin-like growth factor receptor promoter region. Biochem Biophys Res Commun. 1991 Jun 28;177(3):1113-20. To Reference
Ref 5Insulin-like growth factor I receptor gene structure. J Biol Chem. 1992 May 25;267(15):10759-63. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543